Merck Management

Management criteria checks 3/4

Merck's CEO is Rob Davis, appointed in Apr 2021, has a tenure of 3.67 years. total yearly compensation is $20.27M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $35.18M. The average tenure of the management team and the board of directors is 3.9 years and 5.3 years respectively.

Key information

Rob Davis

Chief executive officer

US$20.3m

Total compensation

CEO salary percentage7.9%
CEO tenure3.7yrs
CEO ownership0.01%
Management average tenure3.9yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.81

Dec 02
Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.81

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Oct 15
Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck Is At Support And Should Go Higher (Technical Analysis)

Oct 07

Merck Appears Ready To Return To June Highs (Technical Analysis)

Sep 14

Merck's Change To Profit Guidance Provides An Opportunity

Sep 01

CEO Compensation Analysis

How has Rob Davis's remuneration changed compared to Merck's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$12b

Jun 30 2024n/an/a

US$14b

Mar 31 2024n/an/a

US$2b

Dec 31 2023US$20mUS$2m

US$365m

Sep 30 2023n/an/a

US$5b

Jun 30 2023n/an/a

US$3b

Mar 31 2023n/an/a

US$13b

Dec 31 2022US$19mUS$2m

US$15b

Sep 30 2022n/an/a

US$15b

Jun 30 2022n/an/a

US$17b

Mar 31 2022n/an/a

US$14b

Dec 31 2021US$14mUS$1m

US$12b

Sep 30 2021n/an/a

US$6b

Jun 30 2021n/an/a

US$4b

Mar 31 2021n/an/a

US$5b

Dec 31 2020US$7mUS$1m

US$5b

Sep 30 2020n/an/a

US$9b

Jun 30 2020n/an/a

US$9b

Mar 31 2020n/an/a

US$9b

Dec 31 2019US$8mUS$1m

US$6b

Sep 30 2019n/an/a

US$9b

Jun 30 2019n/an/a

US$9b

Mar 31 2019n/an/a

US$8b

Dec 31 2018US$7mUS$1m

US$6b

Sep 30 2018n/an/a

US$3b

Jun 30 2018n/an/a

US$1b

Mar 31 2018n/an/a

US$2b

Dec 31 2017US$6mUS$1m

US$2b

Compensation vs Market: Rob's total compensation ($USD20.27M) is above average for companies of similar size in the US market ($USD12.67M).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.


CEO

Rob Davis (57 yo)

3.7yrs

Tenure

US$20,273,287

Compensation

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Davis
Chairman3.7yrsUS$20.27m0.014%
$ 35.2m
Caroline Litchfield
Executive VP & CFO3.7yrsUS$8.30m0.0020%
$ 5.1m
Richard DeLuca
Executive VP & President of Merck Animal Health13.3yrsUS$6.20m0.0060%
$ 15.3m
Sanat Chattopadhyay
Executive VP & President of Merck Manufacturing Division15.1yrsUS$6.24m0.0062%
$ 15.9m
Dean Li
Executive VP & President of Merck Research Laboratories7.1yrsUS$9.78m0.0018%
$ 4.7m
Dalton Smart
Senior VP of Financeless than a yearno data0.00018%
$ 459.9k
David Williams
Executive VP and Chief Information & Digital Officerno datano data0.00079%
$ 2.0m
Peter Dannenbaum
Vice President of Investor Relations5.3yrsno datano data
Jennifer Zachary
Executive VP & General Counsel6.7yrsUS$5.90m0.0012%
$ 3.0m
Cristal Downing
Executive VP and Chief Communications & Public Affairs Officer3.3yrsno datano data
Betty Larson
Executive VP & Chief Human Resources Officerless than a yearno datano data
Johannes Oosthuizen
Senior VP & President Merck U.S. Human Health3.9yrsno data0.00094%
$ 2.4m

3.9yrs

Average Tenure

56yo

Average Age

Experienced Management: MRK's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Davis
Chairman3.4yrsUS$20.27m0.014%
$ 35.2m
Pamela Craig
Independent Director9.3yrsUS$400.00k0.000070%
$ 178.8k
Patricia Russo
Independent Director29.3yrsUS$360.00k0.00052%
$ 1.3m
Thomas Glocer
Independent Lead Director17.1yrsUS$430.10k0.00020%
$ 511.0k
Risa Lavizzo-Mourey
Independent Director4.6yrsUS$365.00k0.000040%
$ 102.2k
Douglas Baker
Independent Director2.6yrsUS$347.64k0.000040%
$ 102.2k
Inge Thulin
Independent Director6.8yrsUS$340.00k0%
$ 0
Stephen Mayo
Independent Director3.8yrsUS$350.00k0%
$ 0
Kathy Warden
Independent Director4.8yrsUS$350.00k0.000020%
$ 51.1k
Christine Seidman
Independent Director4.8yrsUS$350.00k0%
$ 0
Paul Rothman
Independent Director9.3yrsUS$380.00k0%
$ 0
Mary Coe
Independent Director5.8yrsUS$342.36k0%
$ 0

5.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: MRK's board of directors are considered experienced (5.3 years average tenure).